Yagami (TSE:7488) Stock Income Appeal Runs Into Payout Strain

Yagami stock has been grinding higher, with a modest 7 day and 90 day gain, yet the real story sits in the earnings tape rather than the price chart. The market is paying up for this healthcare stock, with a P/E of 16.5x against lower sector averages, even as the latest look at the balance between earnings power and valuation raises harder questions.

The headline this season is strain. A rich multiple, a share price above estimated cash flow value and a 6.27% dividend that is not well covered leave investors weighing income appeal against balance sheet and payout pressure.

Love Yagami’s 6.27% income stream but concerned about payout pressure and coverage? Check out our list of income stocks with sturdier balance sheets in the 31 dividend fortresses

Q1 2027 Earnings Summary

• Total Revenue (TTM to Q4 2026): ¥11,502 million vs. ¥10,875 million in the prior TTM period (trailing sales increased over the period)
• Net Income from Continuing Operations (TTM to Q4 2026): ¥1,588 million vs. ¥1,377 million in the prior TTM period (net income was 22.1% higher year over year)
• Basic EPS (TTM to Q4 2026): ¥302.75 per share vs. ¥248.03 per share in the prior TTM period (earnings per share rose in line with net income)
• Net Profit Margin (TTM to Q4 2026): 13.8% vs. 12% in the prior year period (indicating higher profit generated from each yen of revenue)

Prefer clean charts over another wall of financial text and payout ratios for Yagami? Get a full visual view of Yagami’s dividend history and payout sustainability in our company report for Yagami.

Yagami earnings and the institutional bull story

For investors who see Yagami as a steady institutional supplier, the latest trailing numbers lean in your favour. Revenue and net income from continuing operations both moved higher over the year, and net profit margin stepped up from 12% to 13.8%. That points to a business that is not just selling more, but also keeping more of each yen. For a company anchored in education and healthcare equipment, this combination of higher sales and firmer margins fits the narrative of a solid, repeat order driven model.

Income strain keeps the cautious Yagami view alive

The bear case around income risk and balance sheet pressure is not fully answered yet. Yagami offers a 6.27% dividend yield while earnings, although higher, are being stretched over that payout. Rising profit and margin improvement help, but they do not remove concerns about the sustainability of such a high yield if trading conditions soften. Recent share price gains over 7 and 90 days are modest, which suggests the market is not rushing to re rate this as a low risk income story without further proof.

Review Yagami’s stretched 6.27% dividend coverage and see whether this pressure is just one warning sign among others in our risk analysis for Yagami which shows 1 important warning sign.

Take Control of Your Next Move

If Yagami’s richer P/E, higher margins and stretched 6.27% yield have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more comfortable entry point. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the key updates that matter for your holdings. For a longer term view, tap into the Community to see how other investors are thinking about risks and potential catalysts around Yagami. By spotting emerging strengths and pressure points early, you can make faster decisions and stay a step ahead of the market.

Seeking Alternatives Beyond Yagami Now

Market windows move fast. Fresh ideas can gain breakout momentum or get caught dropping back to earth before the crowd notices. Scan these under the radar opportunities while it matters and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com